Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 3
2014 2
2015 6
2016 3
2017 2
2018 2
2019 2
2020 1
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Di Giacomo AM, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, Giannarelli D, Petitprez F, Lacroix L, Valente M, Cutaia O, Fazio C, Amato G, Lazzeri A, Monterisi S, Miracco C, Coral S, Anichini A, Bock C, Nemc A, Oganesian A, Lowder J, Azab M, Fridman WH, Sautès-Fridman C, Trajanoski Z, Maio M. Di Giacomo AM, et al. Among authors: cutaia o. Clin Cancer Res. 2019 Dec 15;25(24):7351-7362. doi: 10.1158/1078-0432.CCR-19-1335. Epub 2019 Sep 17. Clin Cancer Res. 2019. PMID: 31530631 Clinical Trial.
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Cutaia O, Amato G, Covre A, Camerini R, Calabrò L, Valente M, Giannarelli D, Mandalà M, Maio M. Di Giacomo AM, et al. Among authors: cutaia o. Clin Cancer Res. 2021 Sep 1;27(17):4737-4745. doi: 10.1158/1078-0432.CCR-21-1046. Epub 2021 Jun 10. Clin Cancer Res. 2021. PMID: 34112708 Clinical Trial.
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.
Lofiego MF, Cannito S, Fazio C, Piazzini F, Cutaia O, Solmonese L, Marzani F, Chiarucci C, Di Giacomo AM, Calabrò L, Coral S, Maio M, Covre A, On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators. Lofiego MF, et al. Among authors: cutaia o. Epigenomes. 2021 Dec 14;5(4):27. doi: 10.3390/epigenomes5040027. Epigenomes. 2021. PMID: 34968251 Free PMC article.
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, Palmieri G, Giannarelli D, Covre A, Maio M. Calabrò L, et al. Among authors: cutaia o. Lancet Respir Med. 2021 Sep;9(9):969-976. doi: 10.1016/S2213-2600(21)00043-6. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844995 Free PMC article.
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.
Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Cutaia O, Fonsatti E, Parmiani G. Maio M, et al. Among authors: cutaia o. Cancer Immunol Immunother. 2013 Dec;62(12):1851-8. doi: 10.1007/s00262-013-1496-5. Epub 2013 Nov 5. Cancer Immunol Immunother. 2013. PMID: 24190546 Free PMC article. No abstract available.
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.
Fazio C, Covre A, Cutaia O, Lofiego MF, Tunici P, Chiarucci C, Cannito S, Giacobini G, Lowder JN, Ferraldeschi R, Taverna P, Di Giacomo AM, Coral S, Maio M. Fazio C, et al. Among authors: cutaia o. Front Pharmacol. 2018 Dec 7;9:1443. doi: 10.3389/fphar.2018.01443. eCollection 2018. Front Pharmacol. 2018. PMID: 30581389 Free PMC article.
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.
Sottile R, Tannazi M, Johansson MH, Cristiani CM, Calabró L, Ventura V, Cutaia O, Chiarucci C, Covre A, Garofalo C, Pontén V, Tallerico R, Frumento P, Micke P, Maio M, Kärre K, Carbone E. Sottile R, et al. Among authors: cutaia o. Int J Cancer. 2019 Oct 15;145(8):2238-2248. doi: 10.1002/ijc.32363. Epub 2019 May 13. Int J Cancer. 2019. PMID: 31018250 Free article.
22 results